# Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability

> **NCT01682408** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 28 (actual)

## Conditions studied

- Pharmacokinetics

## Interventions

- **DRUG:** Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)
- **DRUG:** Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed
- **DRUG:** Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)
- **DRUG:** Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B)
- **DRUG:** Ranitidine

## Key facts

- **NCT ID:** NCT01682408
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2012-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01682408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01682408, "Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01682408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*